Capsugel and Pulmatrix Collaborate on Pulmonary Disease Treatments

Article

The collaboration will allow the companies to develop and manufacture novel inhaled therapeutics.

Capsugel and Pulmatrix formed a collaboration to develop and manufacture novel inhaled therapeutics for pulmonary diseases, according to a Feb. 16, 2016 press announcement from the companies. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE -based inhaled therapeutic candidates being developed by Pulmatrix and its potential development partners.

iSPERSE is a dense and dispersible-engineered particle technology that enables pulmonary delivery of drugs with high delivery efficiency, dose reproducibility, and flow-rate independence. Several products leveraging the iSPERSE platform are in development, two of which are a clinical stage bronchodilator (PUR0200) for chronic obstructive pulmonary disease, and an inhaled anti-fungal (PUR1900) for cystic fibrosis.

“This collaboration provides us with access to Capsugel’s spray dry technology, scale-up capabilities, and state-of-the-art equipment to support our growing pipeline of internal and partnered development programs,” said Robert Clarke, PhD, CEO of Pulmatrix in a press announcement.

Source: Capsugel

Recent Videos
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content